Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced that Howard Schiller has been appointed interim chief executive officer, effective immediately. The company said Michael Pearson remains in the hospital where he is being treated for severe pneumonia, and as the timing of his expected return is uncertain, he will be on a medical leave of absence until further notice.
Schiller served as Valeant's CFO from December 2011 through June 2015 and currently serves on Valeant's Board.
Valeant also announced that Robert Ingram, Lead Independent Director, will serve as interim chairman of the Board.
For comments and feedback: editorial@rttnews.com